Outcomes in COVID-19 levilimab studies

0 0.5 1 1.5+ All studies 0% 1 206 Improvement, Studies, Patients Relative Risk Mortality 0% 1 206 ICU admission 70% 1 206 RCTs 0% 1 206 Late 0% 1 206 Levilimab for COVID-19 c19early.org December 2025 Favorslevilimab Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 study c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 70% 0.30 [0.09-1.06] 3/103 10/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.061 Late treatment 70% 0.30 [0.09-1.06] 3/103 10/103 70% lower risk All studies 70% 0.30 [0.09-1.06] 3/103 10/103 70% lower risk 1 levilimab COVID-19 ICU result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.061 Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 serious outcome c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 RCT mortality result c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 1. Late treatment 0% 1.00 [0.26-3.89] 4/103 4/103 no change All studies 0% 1.00 [0.26-3.89] 4/103 4/103 no change 1 levilimab COVID-19 peer reviewed studies c19early.org December 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 1. Effect extraction pre-specified(most serious outcome) Favors levilimab Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ CORONA Lomakin (DB RCT) 0% 1.00 [0.26-3.89] death 4/103 4/103 Improvement, RR [CI] Treatment Control CORONA Lomakin (DB RCT) 70% 0.30 [0.09-1.06] ICU 3/103 10/103 CORONA Lomakin (DB RCT) 65% 0.35 [0.21-0.57] no improv. 16/103 46/103 Levilimab COVID-19 outcomes c19early.org December 2025 Favors levilimab Favors control